Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.50 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25100671 | 0.95 | ADORA1 (0.62) | ADORA1RNASELADORA2AADORA2B | |
| SCHEMBL32671743 | 0.92 | RNASEL (0.57) | ADORA1RNASELENPP1P2RY1P2RY12 | |
| SCHEMBL19645975 | 0.89 | ADORA2A (0.53) | ADORA1ADORA2AADORA2B | |
| Phosphoric Acid SCHEMBL5747244 | 0.88 | CYP2C19 (0.58) | ADORA1ADORA2AADORA2B | |
| SCHEMBL31685400 | 0.87 | ADORA1 (0.52) | ADORA1RNASELCA5AADORA2AADORA2B | |
| SCHEMBL31685735 | 0.87 | ADORA1 (0.52) | ADORA1RNASELCA5AADORA2AADORA2B | |
| SCHEMBL31685223 | 0.87 | ADORA1 (0.58) | ADORA1RNASELCA5AADORA2AADORA2B | |
| SCHEMBL31685397 | 0.86 | ADORA1 (0.55) | ADORA1RNASELCA5AP2RY1 | |
| SCHEMBL62505 | 0.85 | CYP2C19 (0.62) | ADORA1ADORA2AADORA2B | |
| SCHEMBL343478 | 0.85 | CYP2C19 (0.62) | ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | ADORA1 935/4885RNASEL 10/4885CA5A 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.